Mometasone furoate is a small molecule commercialized by Lyra Therapeutics, with a leading Phase III program in Rhinosinusitis. According to Globaldata, it is involved in 5 clinical trials, of which 2 were completed, and 3 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Mometasone furoate’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Mometasone furoate is expected to reach an annual total of $243 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Mometasone furoate Overview

LYR-210 is under development for the treatment of chronic rhinosinusitis in surgically-naive patients. The drug candidate is a long acting formulation of steroid mometasone furoate. It is developed based on the XTreo transmucosal therapeutic system and administered through transmucosal and nasal routes as implant. The technology provides the delivery of drug through the polymeric matrix, to contour to the treatment area (into the sinonasal tissues) and adapt to inflamed remodeling tissue. The drug candidate acts by targeting the glucocorticoid receptor.

Lyra Therapeutics Overview

Lyra Therapeutics is a biotechnology company that specializes in developing commercialization of therapies for treatment of patients with chronic rhinosinusitis and deliver medicines directly to affected tissue for sustained periods. It is headquartered in Watertown, Massachusetts, the US.
The company reported revenues of (US Dollars) US$1.6 million for the fiscal year ended December 2023 (FY2023), an increase of 14.3% over FY2022. The operating loss of the company was US$67.1 million in FY2023, compared to an operating loss of US$56.3 million in FY2022. The net loss of the company was US$62.7 million in FY2023, compared to a net loss of US$55.3 million in FY2022.

For a complete picture of Mometasone furoate’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.